Funder
Lundbeck
Otsuka Pharmaceutical Co Ltd
Reference5 articles.
1. Patient functioning, life engagement, and treatment goals in schizophrenia;Correll;J Clin Psychiatry,2022
2. Medication adherence and discontinuation of aripiprazole once-monthly 400mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar I disorder: a real-world study using US Claims Data;Yan;Adv Ther,2018
3. Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with schizophrenia in a randomized, open-label, parallel-arm, pivotal study;Citrome;J Clin Psychiatry,2023
4. A randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-month long-acting injectable in adults with schizophrenia or bipolar I disorder;Harlin;CNS Drugs,2023
5. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials;Oya;Neuropsychiatr Dis Treat,2015